NATICK, Mass., May 18 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that results from several clinical studies designed to determine the safety and efficacy of its leading endoscopic technologies will be announced at Digestive Disease Week® (DDW), which runs from May 19 to 24 in Washington D.C. In addition, the Company is formally launching the SpyGlass™ Direct Visualization System for single- operator duodenoscope assisted cholangiopancreatoscopy.
"We are pleased to formally introduce the SpyGlass Direct Visualization System, which provides unprecedented, direct visualization of the bile ducts, and requires only a single physician operator," said Michael P. Phalen, President, Boston Scientific Endoscopy. "In addition, this year's DDW provides an opportunity to present results from clinical studies involving our leading endoscopic technologies. We continually strive to update our technology such as the newest version of the WallFlex® Enteral Stents and Radial Jaw® 4 Jumbo Forceps to enhance the quality of life for patients."
Schedule of Events (Partial Listing) Sunday, May 20 (all times are ET) -- Efficacy of Radial Jaw® 4 Biopsy Forceps for Endoscopic Surveillance in Barrett's Esophagus A poster presentation reports the results of a 10-patient study examining the histopathologic differences between using Boston Scientific's new jumbo Radial Jaw 4 (RJ4) forceps and the standard biopsy forceps, Radial Jaw® 3 Biopsy Forceps, for performing endoscopic surveillance in patients with Barrett's Esophagus. The poster presentation, "Efficacy of a New Jumbo Forcep on Histopathology in Barrett's Esophagus" was prepared by Sri Komanduri, M.D., M.S., and will be available from 8:00 a.m. - 5:00 p.m. in Hall E. Monday, May 21 -- ERCP with the SpyGlass™ System Detects Reason for Patient's Acute Pancreatitis A poster presentation prepared by Mansour A. Parsi, M.D., reports on a case involving a 62-year old female patient with recurrent acute pancreatitis and mildly elevated LFTs with a dilated biliary tree. The presentation compares results of diagnosis using conventional ERCP versus ERCP with cholangioscopy using the SpyGlass System. The presentation will be available from 8:00 a.m. - 5:00 p.m. in Room 140. -- Biliary Stone Extraction using SpyGlass Direct Visualization System At 10:30 a.m., an oral presentation entitled, "Biliary Stone Extraction (BSE) Guided by Direct Visualization using the New SpyGlass Direct Visualization System," will be given by Peter D. Stevens, M.D., in room 140. The presentation will report on a 15- patient study that examined the use of the SpyGlass System to guide biliary electrohydraulic lithotripsy. All patients required cholangioscopy-directed BSE after failed conventional ERCP techniques. Tuesday, May 22 -- Efficacy of WallFlex® Enteral Stent in Malignant Gastric Outlet Obstruction This prospective, open, multicenter clinical trial involving 51 patients studied the efficacy of the WallFlex® Enteral Stent in patients who had symptoms from malignant gastro-duodenal obstruction due to incurable distal gastric, periampullary or duodenal malignancy. The main cause of the patients' gastric outlet obstruction was pancreatic cancer. The poster presentation prepared by Jeanin van Hooft et al entitled, "Efficacy of a New Nitinol Enteral Stent (WallFlex) in Malignant Gastric Outlet Obstruction: A Prospective, Open, Multicenter Clinical Trial," will be available from 8:00 a.m. - 5:00 p.m. in Hall E. -- Prospective Study of WallFlex® Colonic Stent for Acute Bowel Obstruction This study, conducted from May 2004 to September 2006, evaluated the efficacy and safety of the WallFlex Colonic Stent for acute bowel obstruction due to primary or recurrent colonic adenocarcinoma. The poster presentation prepared by Giuseppe De Caro et al entitled, "Treatment of Acute Malignant Colorectal Obstruction with WallFlex Colonic Stents," will be available from 8:00 a.m. - 5:00 p.m. in Hall E. -- SpyGlass™ Direct Visualization System: Preliminary Clinical Experiences in Three Centers Simon Lo, M.D., of Cedars-Sinai Medical Center, reports on the clinical experiences of biliary endoscopists and their staffs at Cedars-Sinai Medical Center (Los Angeles), Virginia Mason Medical Center (Seattle), and the University of Pittsburgh Medical Center with the SpyGlass System. Dr. Lo will present the findings at 4:00 p.m. in Room 145.
Boston Scientific will present its latest innovations at booth #2401. The Company will also offer hands-on product demonstration sessions of the SpyGlass Direct Visualization System, WallFlex® Enteral Stents, RX Biliary System™, Polyflex® Esophageal Stents, Radial Jaw® 4 Biopsy Forceps, Resolution® Clip, and the CRE™ Balloon Dilators in its Simulated Clinical Endoscopy Suite.
About Digestive Disease Week®
DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 19-24, 2007, at the Washington Convention Center, Washington, DC. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit http://www.ddw.org/.
About Boston Scientific Endoscopy
Boston Scientific Endoscopy offers a wide range of endoscopic solutions to diagnose and treat gastrointestinal diseases. We are committed to developing new technologies in collaboration with GI physicians to improve patient outcomes through greater procedural efficiency and less-invasive diagnostic and therapeutic options.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.
CONTACT: Paul Donovan 508-650-8541 (office) 508-667-5165 (mobile) Media Relations Boston Scientific Corporation Dan Brennan 508-650-8538 (office) 617-459-2703 (mobile) Investor Relations
SOURCE: Boston Scientific Corporation
CONTACT: Paul Donovan, Media Relations, +1-508-650-8541 (office),
+1-508-667-5165 (mobile), or Dan Brennan, Investor Relations, +1-508-650-8538
(office), +1-617-459-2703 (mobile), both of Boston Scientific Corporation